Hyloris Pharmaceuticals SA
Climate Impact & Sustainability Data (2022, 2023)
Reporting Period: 2022
Environmental Metrics
Renewable Energy Share:67% (LégiaPark headquarters)
ESG Focus Areas
- Environmental Sustainability
- Good Health and Well-being of Society
- Responsible Leadership
Environmental Achievements
- Relocated headquarters to BREEAM-accredited LégiaPark, with solar panels covering 67% of energy needs at full capacity.
- Phased out combustible engine vehicles in company fleet, replacing them with PHEVs and BEVs.
Social Achievements
- Increased employee headcount from 21 to 37, doubling the number of nationalities represented in the team (from 6 to 11).
- Implemented hybrid working model with virtual meetings as standard and overnight stays offered for employees commuting to Liège headquarters.
- Hired a dedicated human resources director to focus on employee well-being and safety.
Governance Achievements
- Board of Directors consists of 8 members, including 4 independent directors and 1 female director.
- Established an Audit Committee and a Remuneration and Nomination Committee.
- Implemented a Dealing Code to prevent market abuse.
Climate Goals & Targets
Long-term Goals:
- Maintain or improve diverse workforce with different nationalities and cultural backgrounds.
Medium-term Goals:
- At least one-third of board members to be of a different gender by 2026.
- Increased focus on sustainability factors in supplier selection.
Short-term Goals:
- Achieve 30 portfolio assets before 2025.
Environmental Challenges
- Potential conflicts of interest due to directors' involvement in other pharmaceutical companies.
- Dependence on third-party suppliers for APIs and manufacturing.
- Risks associated with early-stage product development and regulatory approvals.
- Limited operating history and lack of substantial revenue generation.
- Potential impact of geopolitical instability and health crises on operations.
Mitigation Strategies
- Active monitoring and management of conflicts of interest.
- Careful selection and review of suppliers.
- Diversified product pipeline to mitigate risks.
- Strong cash position to support operations.
- Contingency plans to address potential disruptions.
Supply Chain Management
Responsible Procurement
- Reviews product quality, supplier capabilities, consistency, supplier risk, ESG metrics, and policies.
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: UN Sustainable Development Goals
Certifications: BREEAM (LégiaPark)
UN Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 8: Decent Work and Economic Growth
- Goal 5: Gender Equality
Hyloris's commitment to developing innovative and affordable medicines, minimizing environmental impact, ensuring ethical conduct, and promoting social responsibility aligns with these goals.
Reporting Period: 2023
Environmental Metrics
ESG Focus Areas
- Good Health and Well-being of Society
- Environmental Sustainability
- Responsible Leadership
Environmental Achievements
- Relocated R&D lab to BREEAM-certified "Excellent" green building
- Significantly reduced combustible engine vehicles in company car fleet, introducing PHEV and BEV options
Social Achievements
- Increased percentage of women in the company from 40% in 2022 to 48% in 2023
- Incorporated four key values (Passion and drive, Entrepreneurship, Professional excellence, Integrity and accountability) into employees’ annual review procedure
- Launched a 5-year plan for workplace safety encompassing clear processes, safety trainings, and employee well-being initiatives.
Governance Achievements
- Four out of eight Board members classified as Independent Directors in 2023
- Remuneration Committee comprised solely of Non-Executive Directors, with a majority being independent
- Established a dedicated “Dealing Code” to ensure compliance with market regulations
Climate Goals & Targets
Medium-term Goals:
- At least one third of the members of our Board must be of another gender than the other members by 2026
Short-term Goals:
- Accelerate the growth of its product pipeline, aiming to reach 30 products by 2025
Environmental Challenges
- Challenging market conditions
- Temporary suspension of trading of company shares due to inquiries regarding Qliniq product transactions
- Need to improve governance practices
Mitigation Strategies
- Maintaining stable net operating cash outflow compared to 2022
- Working diligently to resolve inquiries regarding Qliniq transactions and improve governance practices
- Appointment of Thomas Jacobsen as Co-CEO while searching for a new independent CEO
- Plan to engage a 3rd party consulting firm specializing in ESG strategy and reporting in 2024
Supply Chain Management
Responsible Procurement
- Increased focus on sustainability factors in the selection procedure for suppliers
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: UNSD
UN Sustainable Development Goals
- Goal 3 (Good Health and Well-being)
Focus on innovation through reformulation and repurposing existing medications to address unmet medical needs